Drug Profile
Research programme: cancer therapeutics - Sanofi-aventis/Dana-Farber
Latest Information Update: 27 Sep 2010
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute
- Developer Dana-Farber Cancer Institute; Sanofi
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 23 Sep 2010 Investigation in Cancer in France (unspecified route)